Gestational diabetes occurs in women, during the 24th to 28th week of pregnancy, due to insufficient secretion of insulin during pregnancy. During pregnancy, a female body undergoes many changes such as human chorionic gonadotropin hormone secretion and weight gain. Women with gestational diabetes are found to be mild thirstier than normal. The treatment strategies for gestational diabetes include monitoring of blood sugar, healthy diet, and exercise. Novo Nordisk A/S is in the process of developing metformin that decreases the hepatic glucose production, for the treatment of gestational diabetes. AstraZeneca plc is in the process of developing DAPA/MET (a combination of dapagliflozin and metformin) for the treatment of the disease. Some of the companies having a pipeline of gestational diabetes include Boehringer Ingelheim GmbH, Novo Nordisk A/S, AstraZeneca plc, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.